76910-02-6Relevant articles and documents
Synthesis of Polycycles by Single or Double Domino Nucleophilic Substitution/Diels-Alder Reaction
Camps, Pelayo,Lozano, David,Font-Bardia, Mercè
, p. 5013 - 5020 (2015)
New hexacyclo and octacyclo compounds have been synthesized by a short route whose key step consists of a single or double domino nucleophilic substitution of neopentyl-type iodides with potassium cyclopentadienide, followed by intramolecular Diels-Alder cycloaddition.
Alkyne-azide click chemistry mediated carbanucleosides synthesis
Broggi, Julie,Joubert, Nicolas,Aucagne, Vincent,Berteina-Raboin, Sabine,Diez-Gonzalez,Nolan, Steve,Topalis, Dimitri,Deville-Bonne, Dominique,Balzarini, Jan,Neyts, Johan,Andrei, Graciela,Snoeck, Robert,Agrofoglio, Luigi A.
, p. 1391 - 1394 (2007)
Hitherto unknown 1,4-disubstituted-[1,2,3]-triazolo-4′,4′- dihydroxymethyl-3′-deoxy carbanucleosides were synthesized based on a "click approach." Various alkynes were introduced on a key azido intermediate by the "click" 1,3-dipolar Huisgen cycloaddition
Synthesis of 1,3-Cycloalkadienes from Cycloalkenes: Unprecedented Reactivity of Oxoammonium Salts
Nagasawa, Shota,Sasano, Yusuke,Iwabuchi, Yoshiharu
supporting information, p. 13189 - 13194 (2016/10/30)
Few methods allow for the direct conversion of cycloalkenes into cycloalkadienes with high chemo- and regioselectivity. Herein, we report a convenient one-pot process for this transformation that involves the unprecedented N-preferential group transfer of N-oxoammonium salts to cycloalkenes, followed by Cope elimination, to afford cycloalkadienes at room temperature and pressure.
PYRAZOLE DERIVATIVES AND USES THEREOF AS INHIBITORS OF DLK
-
Page/Page column 120, (2015/07/07)
The present invention provides for compounds of formula 0 and various embodiments thereof, and compositions comprising compounds of formula 0 and various embodiments thereof. In compounds of formula 0, the groups R1A, R1B, R1C, R1D, R2, R3, R4, R5 and R6 have the meaning as described herein. The present invention also provides for methods of using compounds of formula 0 and compositions comprising compounds of formula 0 as DLK inhibitors and for treating neurodegeneration diseases and disorders.